It is expected that a combination of transcatheter arterial chemoembolization (TACE) with stereotactic body radiation therapy (SBRT) may induce synergistic therapeutic effects in hepatocellular carcinoma (HCC), which would result in a high rate of complete therapeutic response. In this study, we present the 5-year clinical course of a patient who had HCC at the caudate lobe, which was treated with TACE and SBRT. A 53-year-old male was diagnosed with an 8 cm-sized HCC at the caudate lobe with compression of the inferior vena cava (IVC). For fear of pulmonary metastasis, we decided to perform sequential TACE-radiotherapy instead of upfront hepatectomy, although the tumor appeared resectable. The first session of TACE, SBRT with 12 fractions, and the second session of TACE were sequentially performed. The patient was administered metformin for chemoprevention. Over the course of a 5-year follow-up, there was no evidence of HCC recurrence. We reported the clinical sequence of a patient showing complete therapeutic response of HCC at the caudate lobe after a combination of TACE and radiotherapy. This type of combined locoregional treatment can be a therapeutic option for HCC at the caudate lobe with marginal resectability. (Ann Hepatobiliary Pancreat Surg 2018;22:274-281)
INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and is one of the leading causes of cancer-related deaths. 1, 2 Hepatic resection (HR) is considered to be the preferred treatment method for HCC but is also considered to be a challenging surgical procedure in the presence of liver cirrhosis. HR resection for HCC encircling the retrohepatic inferior vena cava (IVC) increases the risk of an intraoperative tumor spread during the handling of the hypervascular mass. [3] [4] [5] [6] Transcatheter arterial chemoembolization (TACE) represents one of the locoregional therapies for HCC. TACE often improves outcomes in patients with unresectable
HCCs, but it has not been considered a curative treatment because of high recurrence rates. We previously reported that preoperative TACE for resectable HCC may adversely affect post-resection prognosis, irrespective of pathological responses. Thus, we suggested that preoperative TACE should be avoided for patients with resectable small HCCs. 7 With recent advances in the radiotherapy techniques, stereotactic body radiation therapy (SBRT) has been considered an alternative treatment option for a small HCC not suitable for hepatic resection and other locoregional treatments. [8] [9] [10] More recently, volumetric-modulated arc therapy, one of the most sophisticated linear acceleratorbased treatment modalities, has become available even with gated delivery. This method allows dose rate-changing intensity modulation with gantry rotation and may provide more conformal dose distribution while reducing treatment delivery time and monitor units.
It is expected that a combination of TACE with SBRT may induce synergistic therapeutic effects, which would Four days later, a liver CT scan was taken, in which some suspected viable tumor portion was found in the lipiodolized HCC (Fig. 6 ). We decided to carry out the pre- Six weeks later, after SBRT, a follow-up CT scan showed a slight decrease in the size of the lipiodol-uptake HCC, in which we could not exclude the possibility of a viable tumor (Fig. 8) . At this time, the serum PIVKA-II level was normalized. Thus, the second session of TACE was performed, in which suspicious tumor staining was found in both lobes, thus chemoinfusion and lipiodol/gelfoam embolization was performed via the right and left hepatic arteries (Fig. 9) . 
DISCUSSION
HCC located at the caudate lobe with encircling involvement of the retrohepatic IVC has often been treated with HR through various surgical approach methods.
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The transhepatic approach, dividing the hepatic parenchyma to expose the paracaval portion, is a feasible method used to reduce the risk of tumor handling-associated tumor spread. Downstaging with preoperative TACE had been attempted, but its therapeutic effect was worse than expected. 7, 11 HR, used only a few months after TACE, should be avoided because the integrity of the HCC cells is loosened, by which the risk of intraoperative tumor spread increases. The preoperative waiting period after TACE is usually recommended to be at least 3-6 months.
So far, it is not recommended to perform any preoperative locoregional treatment of resectable or marginally resectable HCCs located at the caudate lobe. Recently, the therapeutic role of radiotherapy for HCC has been emphasized more than before. The local control rate of SBRT is reported to be similar to that of RFA, 8, 9 which suggests the possibility of SBRT as an ablative xenograft models of tumors with a low alpha/beta ratio. [14] [15] [16] The clinical sequence of our present case appears to be unique. The mass at the caudate lobe grows very slowly, indicating malignant transformation within the dysplastic nodule during follow-up over several years. At the time of admission, this lesion was diagnosed of overt HCC.
During 5-year follow-up after TACE-radiotherapy, it regressed slowly but probably the non-tumorous portion remained. These sequences are not typical, thus not being presented in detail in literature.
In our present case, metformin has been administered for chemoprevention although he was not diabetic.
Metformin is a biguanide agent used to treat type 2 diabetes mellitus. It regulates the blood sugar by improving insulin sensitivity and reducing hepatic glucose output through inhibition of gluconeogenesis and glycogenolysis. Recently, metformin has proven capable of inhibiting cancer cell growth by inducing cell cycle arrest and enhancing apoptosis. 17 A considerable number of studies have found that metformin plays a chemopreventive role in other cancers and is associated with reduced risk for HCC. 18, 19 We recently presented that the administration of metformin showed a tendency to reduce the tumor recurrence rate and helped induce significant improvement in overall survival in patients who underwent HR for HCC. 20 We suggest administering metformin in HCC patients with glucose intolerance or overt diabetes mellitus.
In conclusion, we presented the clinical sequence of a patient showing complete response of HCC at the caudate lobe after a combination of TACE and radiotherapy. This type of locoregional treatment can be a therapeutic option for HCC at the caudate lobe with marginal resectability.
